Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors

Inken Salewski 1,†, Julia Henne 1,‡, Leonie Engster 1, Bjoern Schneider 2, Heiko Lemcke 3,4, Anna Skorska 3,4, Peggy Berlin 5, Larissa Henze 1, Christian Junghanss 1 and Claudia Maletzki 1,*

1 Department of Medicine, Clinic III–Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany; Inken.salewski@med.uni-rostock.de (I.S.); julia.henne@uni-rostock.de (J.H.); leonie.engster@uni-rostock.de (L.E.); Larissa.henze@med.uni-rostock.de (L.H.); Christian.junghanss@med.uni-rostock.de (C.J.)
2 Institute of Pathology, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany; bjoern.schneider@med.uni-rostock.de
3 Department of Cardiac Surgery, Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany; Heiko.Lemcke@med.uni-rostock.de (H.L.); anna.skorska@med.uni-rostock.de (A.S.)
4 Faculty of Interdisciplinary Research, Department Life, Light & Matter, University Rostock, 18057 Rostock, Germany
5 Division of Gastroenterology and Endocrinology, Department of Medicine II, Rostock University Medical Center, University of Rostock, 18057 Rostock, Germany; peggy.berlin@med.uni-rostock.de

* Correspondence: claudia.maletzki@med.uni-rostock.de
† Authors contributed equally.

Abstract: Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resistance development, combination approaches are warranted. Herein, we applied a combined regimen with an α-PD-L1 antibody and gemcitabine in a preclinical tumor model to activate endogenous antitumor immune responses. Mlh1−/− mice with established gastrointestinal tumors received the α-PD-L1 antibody (clone 6E11; 2.5 mg/kg bw, i.v., q2wx3) and gemcitabine (100 mg/kg bw, i.p., q4wx3) in mono- or combination therapy. Survival and tumor growth were recorded. Immunological changes in the blood were routinely examined via multi-color flow cytometry and complemented by ex vivo frameshift mutation analysis to identify alterations in Mlh1−/− tumor-associated target genes. The combined therapy of α-PD-L1 and gemcitabine prolonged median overall survival of Mlh1−/− mice from four weeks in the untreated control group to 12 weeks, accompanied by therapy-induced tumor growth inhibition, as measured by [18F]-FDG PET/CT. Plasma cytokine levels of IL13, TNFα, and MIP1β were increased and also higher than in mice receiving either monotherapy. Circulating splenic and intratumoral myeloid-derived suppressor cells (MDSCs), as well as M2 macrophages, were markedly reduced. Besides, residual tumor specimens from combi-treated mice had increased numbers of infiltrating cytotoxic T-cells. Frameshift mutations in APC, Tmem60, and Casc3 were no longer detectable upon treatment, likely because of the successful eradication of single mutated cell clones. By contrast, novel mutations appeared. Collectively, we herein confirm the safe application of combined chemo-immunotherapy by long-term tumor growth control to prevent the development of resistance mechanisms.

Keywords: immune checkpoint inhibitor; MMR deficiency; in vivo imaging; tumor microenvironment; genetic model; coding microsatellite mutations
1. Introduction

Conventional oncological treatment regimens include surgery, radiation, and chemotherapy. While the latter is a widely applied treatment option for primary and metastatic diseases, the side effects are complex, including myelosuppression. Cancer immunotherapy is a safe and effective treatment option, and immune-checkpoint inhibitors (ICIs) are widely used nowadays, both in research and clinically to force tumor cell killing via reactivation of exhausted T-cells. Additional to the already established α-PD1 and α-CTLA-4 antibodies, the FDA recently approved atezolizumab, avelumab, and durvalumab as antibodies against PD-L1, because of proven long-lasting immune-responses in certain patient cohorts [1–3].

Lynch Syndrome and constitutional mismatch repair deficiency (dMMR) are two hereditary cancer syndromes with a high likelihood of having a good response towards ICIs. In both syndromes, germline mutations in one of the mismatch-repair genes constitute the oncogenic driver, resulting in early-onset tumorigenesis [4–11]. Lynch Syndrome carriers frequently harbor MLH1 or MSH2 germline mutations, whereas, in constitutional mismatch repair deficiency, germline PMS2 and MSH6 mutations dominate. A hallmark of all dMMR-driven tumors is the high tumor mutational burden, often characterized by frameshift mutations in coding microsatellites (cMS) of tumor suppressor genes. This hyper- or ultra-hypermutated phenotype directly correlates with the level of immunity and contributes to the approval of the α-PD-1 antibody pembrolizumab for 1st-line treatment of patients with unresectable or metastatic dMMR colorectal cancer (CRC) [12,13]. The SAMCO-PRODIGE 54 randomized phase II trial is currently evaluating avelumab vs. standard 2nd-line treatment chemotherapy in metastatic dMMR CRC patients [14]. Additional studies are ongoing, including 1st and 2nd-line treatment schedules (clinical trials.gov).

While the enthusiasm of ICIs is often thwarted by resistance mechanisms and relapse upon successful ICI-tailored therapy, combination therapies are actively tested. A very promising approach is the combination of chemotherapeutics, based on the observation that some drugs activate endogenous antitumor immune responses [15]. These include direct effects such as the induction of immunogenic cell death, but also indirect effects via cytotoxic T cell activation and tumor infiltration. These encouraging results have contributed to the initiation of clinical trials for α-PD-L1-based chemo-immunotherapy to treat solid tumors (NCT03572400, NCT03324282, NCT03093922). Furthermore, even tumors with low mutational load (Lynch syndrome subtype G2) acquire a higher mutational burden by chemotherapy [16,17]. Gemcitabine is among the most promising drugs. Acting like a classical cytotoxic drug by inhibiting DNA synthesis, this substance has the capacity to activate the immune system and shift the tumor microenvironment towards an inflammatory milieu [18,19]. Indeed, in our previous study on Mlh1−/− mice, this drug, in conjunction with a whole tumor vaccine, prolonged survival via immune modulation [20]. To move on, we combined gemcitabine chemotherapy with an α-PD-L1 ICI and analyzed the outcome.

2. Results

2.1. In Vitro Analysis

Two cell lines, A7450 T1 M1 and 328, established from mouse duodenal tumors were used for preliminary in vitro experiments. The former cell line, A7450 T1 M1, was generated upon in vivo expansion, whereas 328 cells could be established from the primary tumor. Both cell lines are highly heterogenic in terms of morphology, growth kinetics, mutational profile, and drug response [21,22]. To test the efficacy of ultra-low-dose chemotherapy (CTX) treatment, a colony formation assay was performed. Figure 1A shows representative crystal violet stainings. Experiments revealed individual responses, with more evident growth inhibition in A7450 T1 M1 cells than in 328 cells (Figure 1A). For the former, cell density was approximately 20% lower after low-dose CTX treatment and remained decreased even after 6 days of rest. For the 328 cells, a decelerated response profile was observed with a lack of initial growth inhibition, but reduced cell numbers after an
additional 6 days of rest, finally reaching an inhibition of 15%. The numbers of viable cell colonies were thus below controls. Then, a semi-autologous short-term co-culture system was used to analyze the impact of the immune system. Tumor and immune cells were co-cultured in the presence of CTX, α-PD-L1, or a combination of both, and residual cells were counted after 72 h via flow cytometry (Figure 1B). Treatment with α-PD-L1 stimulated immune-mediated killing of A7450 T1 M1, but not 328 cells. CTX itself had no influence on tumor cell numbers. The combination of both agents boosted the immune-mediated killing of A7450 T1 M1 cells. Here again, 328 cells were resistant towards killing, and cell numbers even increased (Figure 1B). Then, the immune cells were stained for typical surface antigens to check for activation and exhaustion markers. Numbers of Lag3+/T-lymphocytes increased in the combination (Figure 1C). PD-L1+ and PD-1+ cells were lower in T-lymphocytes exposed to A7450 T1 M1 cells and the combination therapy, while both markers were elevated under α-PD-L1 treatment. No change was seen for the 328-edited lymphocytes, irrespective of the treatment. Likewise, numbers of CD4+CD25+Foxp3+ regulatory T cells were lower in lymphocytes co-cultured with A7450 T1 M1 cells and the combination therapy.

Figure 1. In vitro colony formation assay and co-culture. (A) Colony formation assay. Mlh1−/− cell lines A7450 T1 M1 and 328 were treated for 6 days with gemcitabine. Colonies were counted either directly after treatment or after an additional 6 days of rest. (B) Co-culture of tumor cells with murine immune cells. After 72 h, cells were counted and (C) immune cells were phenotyped. The gating strategy is shown on the right side, next to the bar charts. Events shown within the dot plots represent mean of the numbers of positive cells ± SD resulting from 20,000 events.

Hence, though differences did not reach statistical significance, the above data hinted towards the successful elimination of tumor cells because of immune-editing.
2.2. Combination of α-PD-L1 and CTX Prolongs the Survival of Mlh1<sup>+/−</sup> Mice

Then, we tested our treatment strategy in an in vivo Mlh1<sup>+/−</sup> model (see the workflow, Figure 2). Mice with an already diagnosed gastrointestinal tumor (GIT) received the α-PD-L1 antibody, CTX, a combination of both, or were left untreated (tumor size at the starting point: ≈50 mm<sup>3</sup>). Survival time of the mice was significantly influenced by the different treatments. Monotherapies with either α-PD-L1 or CTX doubled the survival rate from 4 weeks (median survival) to around 6 to 7 weeks (p < 0.05 vs. control). The combination of both therapies has even prolonged overall survival, reaching 12 weeks (p < 0.0001 vs. control, Figure 2B). Accompanying longitudinal tumor volume analysis using [18F]-FDG PET/CT revealed effective tumor growth control in all three treatment groups and significantly decreased tumor size in the combination group (p < 0.05 vs. control, Figure 2C). Although differences were insignificant between treatment groups, we want to emphasize that all mice in the combination group received follow-up screening, whereas only 75% and 50% of mice in the α-PD-L1 and CTX group, respectively, were available for PET/CT screening. The remaining mice had to be euthanatized because of progressive disease. The combination therapy induced stable disease (SD) or partial response (PR) in 43% and 43% of mice, respectively. In the monotherapies, less than 50% of mice experienced SD or PR, and all control mice suffered from progressive disease (Figure 2C).

**Figure 2.** Therapy protocol and Kaplan-Meier survival curve. (A) Schematic therapeutic protocol including PET/CT imaging, blood collection and endpoint procedure. (B) Kaplan-Meier survival curve. Mice were treated with α-PD-L1 (clone 6E11, Genentech, 2.5 mg/kg bw, i.v., q2w), gemcitabine (100 mg/kg bw, i.p., q4wx3, CTX = chemotherapy), or a combination of chemotherapy, followed by α-PD-L1 antibody therapy four weeks later. (C) Tumor progression under therapy, measured with [18F]-FDG PET/CT. The mean tumor volume ± SD in mm<sup>3</sup> are shown. Measurements were taken at start of the respective therapy and 5 weeks later (n = 3–8 mice/group and time-point). * p < 0.05; one-way ANOVA (Dunnett’s multiple comparison test).
2.3. Peripheral Immune Activation by Combinational Therapy

Furthermore, immunological changes in the blood were recorded routinely via flow cytometry (Figure 3). The plasma was analyzed using a multiplex cytokine assay (Figure 3A). IL10 and RANTES concentrations did not change over time in any of the four groups, whereas, in the combination, IL13, TNFα, MIP1β, and EOTAXIN levels increased, which might be due to an increase in cytokine-secreting T cells. Besides, α-PD-L1 monotherapy also increased MIP1β concentration to the same level as the combination treatment. Additional flow cytometric phenotyping of blood samples showed quite similar levels of positive cells in both monotherapy groups, while the combination therapy induced CD3+CD4+ T-helper cells significantly after 12 weeks of treatment \((p < 0.01)\) combination vs. CTX, Figure 3B). Moreover, the CD3+CD8+ cytotoxic T cells increased by trend in the combination group as well as CD83+ cells, indicative of activated B-cells and dendritic cells. The numbers of CD11b+GR1+ myeloid-derived suppressor cells (MDSCs) did not differ between individual treatment groups.

![Figure 3](image-url)

**Figure 3.** Quantification of plasma cytokine levels and assessment of immunologically relevant markers in the blood. (A) Cytokine levels in the plasma were analyzed at beginning of therapy and after 5 weeks. The y-axis shows the mean cytokine levels ± SD. (B) Every four weeks, blood was taken from mice under therapy to investigate immunological changes via flow cytometry. Represented are the numbers of positive cells ± SD resulting from 20,000 events, \(n = 3-5\) mice/group. **p < 0.01 vs. CTX; one-way ANOVA (Bonferroni’s multiple comparison test); †† p < 0.01 vs. α-PD-L1 monotherapy one-way ANOVA (Dunnett’s multiple comparison test).

2.4. Spleens and Residual Tumors Change Their Immunological Profile

At the endpoint, either determined by humane endpoints or after several weeks of follow-up observation, spleens and residual tumors were analyzed using flow cytometry (Figure 4). Similar to the blood, numbers of CD3+CD4+ T-helper cells significantly increased in the spleen after combinational treatment \((p < 0.05)\) control). CD3+CD8+ cytotoxic T cells and CD83+ cells were slightly increased after all three therapies. In contrast, CD11b+GR1+ MDSCs and CD200R+ cells decreased upon treatment. The therapy effect on tumor infiltrating T cells goes hand in hand with the effect in the spleen. All three groups
were characterized by increased T cell levels, reaching significance in the combination (CD3⁺CD8⁺ T cells, p < 0.05 vs. control). The percentage of CD11b⁺GR1⁺ MDSCs was as high as in the control in the monotherapies but decreased significantly after combination therapy. The numbers of CD83⁺ cells did not change considerably but declined in the α-PD-L1 monotherapy. No effect was seen for CD200R⁺ cells, implicating a minor role in the immune regulatory functions of CD200-CD200R interaction.

Figure 4. Flow cytometric phenotyping of spleens and tumor microenvironment. At the endpoint, spleen and tumor were resected. The single cell suspension was stained with respective antibodies and screened for immunological markers via flow cytometry. Represented are the numbers of positive cells ± SD resulting from 20,000 events, n = 3–5 mice/group. * p < 0.05 one-way ANOVA (Bonferroni’s multiple comparison test).

In addition to flow cytometry, the tumor microenvironment was studied in detail by fluorescence microscopy (Figures 5 and 6). The amount of cytotoxic T-lymphocytes was higher upon CTX and the combination treatment. T-helper cells additionally increased by CTX. MDSCs were only visible in the control and CTX groups, and thus effectively eliminated by the α-PD-L1 antibody. M2 macrophages and DCs were present in all groups, but their density and location differed between groups (Figure 5). PD-1 expressing M2 macrophages vanished in the combination, in a similar manner to regulatory granulocytes, which were more abundant in the control and CTX groups. Hence, the α-PD-L1 antibody itself shaped the tumor microenvironment by eradicating immunosuppressive cell populations (i.e., CD11b⁺PD-L1⁺, CD206⁺PD1⁺) and promoting infiltration of antigen-presenting cells (CD11c⁺). In support of this, we also found significantly higher levels of IRF5⁺ cells within tumor sections treated with the α-PD-L1 antibody alone or in combination with CTX (Figure 6A,B). In most cases, IRF5⁺ cells co-localized with PD1⁺ cells in the lymphoid compartment within the tumors (Figure 6C). Hence, IRF5 may constitute a direct indicator for successful immune activation in α-PD-L1-based regimens.
presenting cells (CD11c+). In support of this, we also found significantly higher levels of IRF5+ cells within tumor sections treated with the α-PD-L1 antibody alone or in combination with CTX (Figure 6A,B). In most cases, IRF5+ cells co-localized with PD1+ cells in the lymphoid compartment within the tumors (Figure 6C). Hence, IRF5 may constitute a direct indicator for successful immune activation in α-PD-L1-based regimens.

Figure 5. Immunofluorescence. Mlh1−/− GIT cryostat sections of 4 µm were prepared and the tumor microenvironment was studied upon staining with specific monoclonal antibodies, followed by nuclear staining with DAPI. Images were taken using a laser scanning microscope, Elyra PS.1 (Zeiss), and 20× objective.

Figure 6. IRF5 immunofluorescence. (A) Mlh1−/− GIT cryostat sections of 4 µm were prepared and stained with Alexa488-conjugated anti-PD1 antibody and primary rabbit anti-IRF5 antibody, followed by staining with a secondary Alexa647-labeled antibody. Nuclei were counterstained with DAPI. Pictures were taken on a laser scanning microscope (Zeiss) using 20× objectives. (B) Quantification of IRF5+ infiltrating immune cells. At least three images were taken from each slide and numbers of infiltrating cells counted. Data are given as infiltrates/high power field (HPF). Mean ± SD, n ≥ 3 samples/group; * p < 0.05; ** p < 0.01; *** p < 0.001; one-way ANOVA (Bonferroni’s multiple comparison test). (C) Representative immunofluorescence images show co-localization of IRF5+ cells and PD1+ cells (single planes and merged channels).
2.5. Treatment with α-PD-L1 Induced Molecular Changes in cMS of dMMR-Target Genes

The therapies not only induced immunological changes but also influenced the mutational frequency in Mlh1<sup>−/−</sup> tumors (Figure 7). Both α-PD-L1 monotherapy and combinational therapy increased the overall mutation frequency of the tumor (Figure 7A). Figure 7B shows the mutation frequencies in dMMR-target genes. Frameshift mutations in APC, Tmem60, and Casc3 were no longer detectable upon treatment, likely because of eradicating single mutated cell clones. By contrast, novel mutations appeared (Figure 7B,C). Mutation frequencies in cMS repeats of MDC1 slightly increased after α-PD-L1 monotherapy and CTX. Additionally, cMS mutation frequencies in Senp6, Mbd6, and Lig4 increased after α-PD-L1 monotherapy. Since this trend was not seen in the combination, specific elimination is likely. Lig4 is the only exception. Here, cMS mutations were only detectable upon treatment but remained comparably low in the combination. CTX monotherapy alone triggered mutations in cMS of MDC1, Mbd6, and Lig4.

![Figure 7](image)

**Figure 7.** cMS mutation frequency. (A) Fragment length analysis was used to detect frameshift mutations in selected cMS. Overall mutational frequency in residual tumors revealed higher mutational load after α-PD-L1 monotherapy and the combination. (B) The cMS mutation frequency in selected Mlh1<sup>−/−</sup> target genes differed among the four therapy groups. In some genes, the results even indicated loss of single cell clones (APC, Tmem60, and Casc3). (C) Representative band shifts of two cMS loci in Tmem60 and Senp6 target genes. Wt—wildtype; wt/−1—wildtype/−1 s.

3. Discussion

In the present study, we targeted the PD-1/PD-L1 axis additional to conventional CTX to enhance the survival of Mlh1<sup>−/−</sup> mice. This strategy is based on the idea of utilizing CTX as an immunogenic cell death (ICD) inducer. Indeed, several reports from the literature provided sufficient data confirming ICD induction by cytostatic or cytotoxic drugs. These include, among others, anthracyclines such as doxorubicin, mitoxantrone, and oxaliplatin [23–26]. Besides, we recently described successful ICD induction by the deoxycytidine nucleoside analogue gemcitabine, characterized by reduced amounts of intracellular IDO-1, increased levels of surface-bound CalR, and elevated HMGB1 secretion [20]. To boost CTX-initiated immune responses, we here added an α-PD-L1 antibody and performed in vitro as well as in vivo analyses. Using a semi-autologous in vitro coculture system, we provide evidence for the successful targeting of dMMR epithelial Mlh1<sup>−/−</sup> murine tumor cells. However, the therapeutic outcome was highly individual among the two cell lines, A7450 T1 M1 and 328, nicely reflecting the heterogeneity among dMMR tumors patients, even in cases harboring the same MMR mutation [27,28]. The cell line Mlh1<sup>−/−</sup> 328 is highly resistant and representative of a low-immunogenic subtype [21,22], which was confirmed further in this study. For the A7450 T1 M1 cells, the combination proved superior compared to either monotherapy with CTX or α-PD-L1 blockade. By studying the immune cells’ phenotype in-depth, we identified differences in
specific activation and immune-regulatory markers. Numbers of PD-L1+ and PD-1+ as well as CD4+CD25+Foxp3+ regulatory T cells were exclusively lower in lymphocytes co-cultured with A7450 T1 M1 cells and the combination therapies. In 328 cells, no such differences were seen. Successful elimination of tumor cells is thus a likely result of creating an ICD-mediated inflamed, immunogenic tumor environment that enabled T cell-mediated killing. However, this regimen may only succeed in cases of at least moderate tumor immunity.

Using the Mlh1−/− mouse model, we transferred the therapeutic CTX-α-PD-L1 therapy approach in the preclinical situation. Monotherapy of CTX or α-PD-L1 prolonged the overall survival of tumor-bearing mice, which was additionally improved by applying the combination of both agents. Hence, this setting proved safe and effective in our hands. By applying PET/CT staging, induction of SD or PR was seen in >80% of mice, respectively, and thus confirmed successful long-term effects of the applied regimen. Monotherapy of either agent yielded objective response in roughly 25% of mice, matching with clinical data, in which comparable or even superior response towards ICB compared to CTX monotherapy was already proven [29,30]. By combining immunogenic CTX, outcomes for patients with solid tumors were considerably improved. An example of successful chemo-immunotherapy is the combination of platinum CTX with PD-1/PD-L1 inhibitors [31–33], which has now become the standard 1st-line option for advanced PD-L1+ non-small cell lung cancer [34].

With the aim of inducing long-term immunological memory, longitudinal immune profiling revealed elevated plasma levels of IL13, TNFα, EOTAXIN, and MIP1β in the combination, accompanied by higher numbers of cytokine-secreting T-helper cells. The latter is likely attributable to the α-PD-L1 antibody since MIP1β levels additionally increased under this monotherapy. CTX monotherapy did not influence cytokines, with levels being comparable to controls. Another study on pancreatic carcinomas described the consistently high synthesis of CCL/CXCL chemokines and TGF-β-associated signals by gemcitabine after long-term treatment [35]. Alteration of disease course after combined gemcitabine and α-PD-1 treatment was only reached if mice also underwent genetic or pharmacologic ablation of TGF-β signaling. Though we have not analyzed TGF-β-signaling in depth, one may speculate that if induced at all, the α-PD-L1 antibody itself may have neutralized such effects. In support of this, we detected higher numbers of circulating CD83+ cells as well as CD3+CD8+ cytotoxic T cells in the combination group. Both cell types are involved in immune-mediated inflammation, either as antigen-presenting or effector cells. Hence, the dosing interval seems pivotal. CTX was given here three times with long treatment-free intervals, rendering the establishment of additional immunosuppressive cytokine barriers quite unlikely. Another point worth mentioning is the missing impact on circulating MDSCs. This highly immunosuppressive myeloid subtype is well-known for its capacity to facilitate tumor progression—both directly and indirectly [36–40]. The notion that we did not see any differences in numbers of circulating and splenic MDSCs in any treatment group matches with recent studies [41] and may explain the final relapse of Mlh1−/− tumors. Generally, a high frequency of memory cells and low numbers of immunosuppressive cells are indicative of a good response, though individual differences exist [42]. The Mlh1−/− mouse model is representative for immunosuppressive subtypes, thus, converting immune regulatory cells into pro-inflammatory cell types seem challenging. Still, the combination was able to shape the local tumor microenvironment. This included effective elimination of MDSCs and massive reduction of M2 macrophages even after several weeks of after-care, and vice versa; cytotoxic T lymphocytes increased, attributable to successful re-activation of antigen-driven immune responses. This finding is in line with increasing evidence on a broader remodeling of the tumor microenvironment by ICI than previously anticipated [43]. Although the lymphoid compartment is the main target for ICI, other immune cell populations, including myeloid cells, are affected as well [44]. In support of this, we also found higher levels of IRF5+ cells within tumor sections treated with the α-PD-L1 antibody alone or in the combination, often co-localized with PD1+ cells. IRF5 regulates type I IFN signaling and cytokines/chemokines with lymphocyte-chemotactic
activities, such as RANTES. MIP1α/β and is considered a specific marker of inflammatory macrophages [45]. Such positive immune-modulating effects were mainly attributable to the α-PD-L1 antibody, while the CTX itself shaped the tumor microenvironment less efficiently. Here, numbers of MDSCs remained similar between controls and treated mice. Another recent study even reported boosted intratumoral MDSC accumulation by 5-FU that counteracted T and NK cell infiltration, thus abrogating the anti-tumor efficacy of PD-L1 blockade [46]. Such immunosuppressive effects were not seen in our study. In contrast, a positive effect on the immune system was seen here, by slightly elevated numbers of circulating as well as tumor-infiltrating cytotoxic and T helper cells. Other studies likewise reported very low toxicity on T cells and increased CD8+ cytotoxic T cell infiltration upon combined application of low, non-cytotoxic doses of gemcitabine, a Chk1 Inhibitor, and α-PD-L1 antibody [19,47]. Hence, gemcitabine is indeed a very interesting and promising backbone for combination therapies with ICIs.

While dMMR constitutes a predictive biomarker for ICI-based regimens, recent evidence demonstrates that AT-rich interaction domain 1A (ARID1A) deficiency is associated with high antitumor immunity and good response towards ICI-monotherapy [48]. Indeed, tumors arising in Mlh1−/− mice harbor multiple ARID1A missense mutations, resulting in loss-of-function of this tumor suppressor [22]. Hence, the observed clinical response seen here upon mono- and combination therapy with α-PD-L1 adds another piece of evidence for the causative relevance of ARID1A mutations in dMMR-driven cancers. In support of this, a complete pathologic response after two months of combined mFOLFOX6 with pembrolizumab therapy was recently reported in a Lynch syndrome patient suffering from an ARID1A mutated and tumor mutational burden (TMB) high dMMR CRC [49]. It is therefore tempting to speculate that the combination therapy is indeed beneficial for ARID1A-mutated dMMR tumors. Besides, the finding that PD-L1 expression is generally low in dMMR CRCs and not predictive in response to ICIs [50,51] warrants further investigations on ARID1A mutation status as a predictive biomarker.

Another interesting finding of our current study was the observed striking difference in the mutational profile of the selected cMS marker. The monotherapies as well as their combination altered cMS frequency. Single mutated clones vanished, especially in the combination. By contrast, novel mutations appeared under CTX or ICI monotherapy and provide another explanation for final relapse. Though not analyzed in detail here, we speculate higher TMB after mono- than combination therapy. Notably, the most significant changes were seen after α-PD-L1 monotherapy.

Finally, the patients’ responses towards ICB are so individual, and determinants of such distinct reactions are just at the beginning of being understood. There is an increasing body of evidence pointing towards TMB, immune cell densities, and types in the tumor microenvironment, as well as expression levels of PD-1/PD-L1 and cytokines as legitimate factors. Elucidating the determinants of response and resistance are key to improving treatment strategies prospectively.

4. Materials and Methods

4.1. Cell Culture

Mlh1−/− tumor cells were established in our lab and basically characterized [22,52]. Cells were cultured in DMEM medium, supplemented with 10% FCS (fetal calf serum), 6mM Glutamine, and antibiotics (all from Biochrom, Berlin, Germany). Prior to analysis, cells were harvested, washed with PBS, and counted.

4.2. Colony Formation Assay

Cells were cultured as described above. For colony formation assay, a standard protocol was used as described before [53]. Briefly, 500 cells per well were seeded in a 6 well plate and incubated overnight. Thereafter, cells were treated with 0.24 nM gemcitabine or left untreated. After 6 days medium was removed and remaining cells were stained with 500 µL 0.2% crystal violet for 10 min on a rocking plate. Then, the wells were washed 5
times with PBS. For the second group, drug-containing medium was removed after 6 days, and cells were rested with medium for additional 6 days. Afterwards, the amount of colonies was analyzed using ImageJ-win64.

4.3. Co-Culture Experiments

Harvested cells were stained with 5 µM CMFDA for 15 min at 37 °C. Cells were washed with PBS and seeded in a 24 well plate at a density of 20,000 cells per well. On the next day, 0.24 nM gemcitabine was added. Immune cells were harvested from peripheral blood samples routinely taken from Mlh1−/− mice. Around 100 µL of pooled blood was incubated with erythrocyte lysis buffer (155 mM NH4Cl (MERCK Millipore, Darmstadt, Germany), 10 mM KHCO3 (MERCK Millipore), and 0.1 mM EDTA (Applichem, Darmstadt, Germany)) for 15 min, then stopped with PBS. Approximately 200,000 blood cells (E:T ratio: 1:10) were seeded per well. After 24 h, α-PD-L1 (10 µg/mL) was added. Tumor cells were counted with fluorescent microsphere beads (1.4 × 10^5 beads/mL, size: 10 µm, Polysciences, Hirschberg an der Bergstrasse, Germany) on a Flow Cytometer (BD FACSVerse™, BD Pharmingen, Heidelberg, Germany). Data analysis was performed using BD FACSuite software (BD Pharmingen). Additionally, immune cells were stained with a panel of conjugated monoclonal antibodies (mAb, 0.125 µg to 1.5 µg each) and measured on a spectral flow cytometer (Cytek™ Aurora, Amsterdam, The Netherlands). Data were analyzed using SpectroFlow™ Version 2.2.0.3.

4.4. Mlh1−/− Mouse Model and In Vivo Treatment Protocol

4.4.1. Institutional Review Board Statement

The German local authority approved all animal experiments on 27 June 2017: “Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern” (approval number: 7221.3-1-026/17; -026/17-3), under the German animal protection law and the EU Guideline 2010/63/EU. Mice were bred in the animal facility of the University Medical Center in Rostock under specific pathogen-free conditions. Mlh1 genotyping was done according to [21]. During their whole life-time, all animals got enrichment in the form of mouse-igloos (ANT Tierhaltungsbedarf, Buxtehude, Germany), nesting material (shredded tissue paper, Verbandmittel GmbH, Frankenberg, Germany), paper roles (75 × 38 mm, H 0528–151, ssniff-Spezialdiäten GmbH, Cologne, Germany), and wooden sticks (40 × 16 × 10 mm, Abedd, Vienna, Austria). During the experiment, mice were kept in type III cages (Zoonlab GmbH, Castrop-Rauxel, Germany) at 12-h dark:light cycle, the temperature of 21 ± 2 °C, and relative humidity of 60 ± 20% with food (pellets, 10 mm, ssniff-Spezialdiäten GmbH, Soest, Germany) and tap water ad libitum.

4.4.2. Experimental Protocol

Mice with PET/CT proven GIT (located in the duodenum) were taken into therapy. α-PD-L1 antibody (clone 6E11, kindly provided by Genentech, a subsidiary of Roche, South San Francisco, CA, USA) was dissolved in PBS and given intravenously (dose: 2.5 mg/kg bw, n = 10 mice) every 2 weeks, and gemcitabine (CTX, 100 mg/kg bw) intraperitoneal every 4 weeks (n = 10 mice), for a total of 3 times. In combination (n = 9 mice), CTX was given first, and after four weeks, α-PD-L1 antibody treatment started. Control mice were untreated (n = 9 mice). A treatment schedule is depicted in Figure 1. To prevent suffering of the mice, soaked pellets were offered and, additionally, humane endpoints (weight loss >15%, pain/distress, changes in social behavior) were applied. Before mice became moribund, they were sacrificed and blood, spleen, lymph nodes and GIT were removed for further analyses.

4.5. PET/CT Imaging

PET/CT imaging scans were performed on a small animal PET/CT scanner (Inveon PET/CT, Siemens Medical Solutions, Knoxville, TN, USA) according to a standard protocol as described before [54,55]. The PET image reconstruction method consisted of a
2-dimensional ordered subset expectation maximization algorithm (2D-OSEM) with four iterations and six subsets. Attenuation correction was performed on the basis that whole-body CT scan and a decay correction for [18F] was applied. PET images were corrected for random coincidences, dead time, and scatter. By marking the entire tumors, starting at the edge and cutting through the whole [18F]FDG-enriched tumor, volumes and SUVs were determined using Inveon Research Workplace 4.2 software (Siemens Medical Solutions USA, Knoxville, Tennessee).

4.6. Immune Phenotyping

Blood samples were taken from anaesthetized mice every 6 weeks (retrobulbar venous plexus). Single cell suspensions of spleens and GIT were obtained upon passing them through a cell strainer (100 µm). Samples (2 × 10⁵/well) were stained with a panel of conjugated monoclonal antibodies (mAb, 1 µg each) followed by lysis of erythrocytes. Negative controls consisted of lymphocytes stained with the appropriate isotypes (Biolegend, San Diego, CA, USA) or unstained cells. Cells were washed, solved in PBS, and analyzed on a flow cytometer (BD FACVerse™, BD Pharmingen). Data analysis was performed using BD FACSuite software (BD Pharmingen).

4.7. Procartaplex Cytokine Assay

Cytokine levels in plasma samples were determined according to the manufacturer’s instructions of the Procartaplex™ multiplex immunoassay (Thermo Fisher Scientific, Schwerte, Germany). Measurement and cytokine quantification was performed on a Bioplex 2000 (Bio-Rad Laboratories GmbH, Munich, Germany) in combination with the Bio-Plex Manager Software. Absolute plasma cytokine and chemokine level are presented [pg/mL].

4.8. Fragment Length Analysis of cMS Target Genes

Fragment length analysis was done from multiplexed PCRs of gDNA (25 ng/sample) from tumor and normal tissue as described [22]. To identify potential Mlh1 target genes, a panel (n = 20 marker) was screened. Primers were designed using Primer3 software (Elixir Estonia, Tartu, Estonia) to yield short amplicons (≤ 200 bp). Frameshift mutations were detected by mono- and/or biallelic band shifts, usually characterized by deletions.

4.9. Immunofluorescence

Air-dried cryostat sections (4 µm thickness) were fixed (methanol, 8 min). Unspecific binding sites were blocked in 2% BSA (Roth, Karlsruhe, Germany) for 1 h followed by incubation with 1 µg of the following AlexaFluor488, AlexaFluor594, and AlexaFluor 647-labeled mAbs: CD4, CD8α, CD11b, Gr1, CD11c, F4/80, CD104, CD206, PD-1, and PD-L1 (all from Biolegend). For intracellular stainings, slides were fixed in 4% paraformaldehyde w/o methanol (Thermo Scientific, Darmstadt, Germany, 30 min) and cells permeabilized in 0.5% Triton X-100 (Sigma-Aldrich, Darmstadt, Germany, 15 min). After blocking with 2% BSA (Serva, Heidelberg, Germany), slides were incubated with the monoclonal rabbit anti-IRF5 antibody (1:50; ThermoFisher Scientific, Darmstadt, Germany) overnight at 4°C, followed by a secondary goat anti-rabbit Alexa647 antibody (1:500; Cell Signaling, Frankfurt am Main, Germany). Sections were washed, embedded in Roti Mount Flour Care DAPI (Roth), and target proteins visualized on a confocal laser scanning microscope (Elyra 7, Zeiss, Jena, Germany) using 20× objectives. IRF5+ cells were quantified by counting individual positive cells in three high power fields per sample (n = 3/group).

4.10. Statistics

All values are expressed as mean ± SD. After proving the assumption of normality (Kolmogorov-Smirnov test), differences between vaccinated and control mice were determined using the unpaired Student’s t-test or one-way ANOVA (Bonferroni or Dunnnett’s multiple comparison). Kaplan-Meier survival analysis was done by applying the log rank
(Mantel Cox) test. Statistical analyses were performed using GraphPad Prism 8.0.2 (San Diego, CA, USA). The criterion for significance was set to \( p < 0.05 \).

5. Conclusions

The combination of gemcitabine and \( \alpha \)-PD-L1 prolongs the lifetime of Mlh1\(^{-/-}\) mice significantly via long-term tumor growth control. The treatment modulates the tumor microenvironment by eliminating MDSCs and massive reductions of M2 macrophages counterbalanced by an increase in cytotoxic T cells. Patients would profit from a combinational chemo- and ICI therapy, to prevent development of resistance mechanisms.

Author Contributions: Conceptualization, C.M.; methodology, C.M., I.S., J.H., and L.E.; software, I.S. and J.H. validation, C.M.; formal analysis, C.M. and I.S.; investigation, C.M.; data curation, C.M., I.S., J.H., and B.S.; writing—original draft preparation, I.S.; writing—review and editing, C.M., H.L., A.S., P.B., and L.H.; visualization, I.S., J.H., and P.B.; supervision, C.M.; project administration, C.M.; funding acquisition, C.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the German research foundation, grant number MA5799/2-2.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the German local authority on 27 June 2017: “Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern” (approval number: 7221.3-1-026/17; -026/17-3), under the German animal protection law and the EU Guideline 2010/63/EU.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are available from the corresponding author upon reasonable request.

Acknowledgments: We gratefully thank Genentech, a subsidiary of Roche, South San Francisco, USA for providing the clone 6E11 for in vivo experiments. We additionally thank Ilona Klammuss and Chantal von Hörsten for breeding mice, Brigitte Vollmar and Bernd Krause for their continuous support in their efforts of chairing the Core Facility of Multimodal Small Animal Imaging. We also gratefully acknowledge the excellent technical assistance of Joanna Förster, as well as support from the Core Facility for Cell Sorting & Cell Analysis, Laboratory for Clinical Immunology, University Medical Center Rostock. Furthermore, we thank Carina Berger and Anja Gummesson, radiopharmacy team of the Department of Nuclear Medicine of the University Medical Centre Rostock, for providing 18F-FDG for the small animal PET/CT experiments.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Ning, Y.; Suzman, D.; Maher, V.E.; Zhang, L.; Tang, S.; Ricks, T.; Palmby, T.; Fu, W.; Liu, Q.; Goldberg, K.B.; et al. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist 2017, 22, 743–749. [CrossRef] [PubMed]
2. Pal, S.K.; Hoffman-Censits, J.; Zheng, H.; Kaiser, C.; Tayama, D.; Bellmunt, J. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. Eur. Urol. 2018, 73, 800–806. [CrossRef] [PubMed]
3. Solomon, B.; Young, R.J.; Rischin, D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin. Cancer Biol. 2018, 52, 228–240. [CrossRef] [PubMed]
4. Pearlman, R.; Frankel, W.L.; Swanson, B.; Zhao, W.; Yilmaz, A.; Miller, K.; Bacher, J.; Bigley, C.; Nelsen, L.; Goodfellow, P.J.; et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017, 3, 464–471. [CrossRef] [PubMed]
5. Imai, K.; Yamamoto, H. Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics. Carcinogenesis 2008, 29, 673–680. [CrossRef]
6. Álvaro, E.; Cano, J.M.; García, J.I.; Brandáriz, L.; Olmedillas-López, S.; Arriba, M.; Rueda, D.; Rodríguez, Y.; Cañete, Á.; Arribas, J.; et al. Clinical and molecular comparative study of colorectal cancer based on age-of-onset and tumor location: Two main criteria for subclassifying colorectal cancer. Int. J. Mol. Sci. 2019, 20, 968. [CrossRef]
7. Evrard, C.; Tachon, G.; Randrian, V.; Karayan-Tapon, L.; Tougeron, D. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. *Cancers* 2019, 11, 1567. [CrossRef]

8. Wimmer, K.; Rosenbaum, T.; Messiaen, L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. *Clin. Genet.* 2017, 91, 507–519. [CrossRef]

9. Tabori, U.; Hansford, J.R.; Achatz, M.I.; Kratz, C.P.; Plon, S.E.; Frebourg, T.; Brugieres, L. Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. *Clin. Cancer Res.* 2017, 23, e32–e37. [CrossRef] [PubMed]

10. Bakry, D.; Aronson, M.; Durno, C.; Rimawi, H.; Farah, R.; Alharbi, Q.K.; Alharbi, M.; Shamvil, A.; Ben-Shachar, S.; Mistry, M.; et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. *Eur. J. Cancer* 2014, 50, 987–996. [CrossRef] [PubMed]

11. Aronson, M.; Colas, C.; Shuen, A.; Hampel, H.; Fouliks, W.D.; Baris Feldman, H.; Goldberg, Y.; Muleris, M.; Wolfe Schneider, K.; McGee, R.B.; et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): Recommendations from the international consensus working group. *J. Med. Genet.* 2021. [CrossRef] [PubMed]

12. Tan, E.; Sahin, I.H. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. *Expert Rev. Gastroenterol. Hepatol.* 2021, 1–8. [CrossRef] [PubMed]

13. Trullas, A.; Delgado, J.; Genazzani, A.; Mueller-Berghaus, J.; Migali, C.; Muller-Egert, S.; Zander, H.; Enzmann, H.; Pignatti, F. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. *ESMO Open* 2021, 6, 100145. [CrossRef] [PubMed]

14. Taieb, J.; Andre, T.; El Hajbi, F.; Barbier, E.; Toulele, C.; Kim, S.; Bouche, O.; Di Fiore, F.; Chauvent, M.; Ferrier, H.; et al. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. *Dig. Liver Dis.* 2020, 53, 318–323. [CrossRef] [PubMed]

15. Li, J.-Y.; Chen, Y.-P.; Li, Y.-Q.; Liu, N.; Ma, J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. *Mol. Cancer* 2021, 20, 27. [CrossRef] [PubMed]

16. Seth, S.; Ager, A.; Arends, M.J.; Frayling, I.M. Lynch syndrome—Cancer pathways, heterogeneity and immune escape. *J. Pathol.* 2018, 246, 129–133. [CrossRef]

17. Binder, H.; Hopp, L.; Schweiger, M.R.; Hoffmann, S.; Juhling, F.; Kerick, M.; Zimmermann, B.; Siebert, S.; Grimm, C.; Neri-sissy, L.; et al. Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. *J. Pathol.* 2017, 243, 242–254. [CrossRef] [PubMed]

18. Parente, P.; Parcesepe, P.; Covelli, C.; Olivieri, N.; Remo, A.; Pancione, M.; Latiano, T.P.; Graziano, P.; Maiello, E.; Giordano, G. Crossstalk between the tumor microenvironment and immune system in pancreatic ductal adenocarcinoma: Potential targets for new therapeutic approaches. *Gastroenterol. Res. Pract.* 2018, 2018. [CrossRef]

19. Sen, T.; Della Corte, C.M.; Milutinovic, S.; Cardnell, R.J.; Diao, L.; Ramkumar, K.; Gay, C.M.; Stewart, C.A.; Fan, Y.; Shen, L.; et al. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. *J. Thorac. Oncol.* 2019, 14, 2152–2163. [CrossRef]

20. Maletzki, C.; Wiegele, L.; Nassar, I.; Stenzel, J.; Junghanss, C. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer. *J. Immunother. Cancer* 2019, 7, 1–4. [CrossRef]

21. Salewski, I.; Gladbach, Y.S.; Kuntoft, S.; Irmscher, N.; Hahn, O.; Junghanss, C.; Maletzki, C. In vivo vaccination with cell line-derived whole tumor lysates: Neoantigen quality, not quantity matters. *J. Transl. Med.* 2020, 18, 1–5. [CrossRef]

22. Gladbach, Y.S.; Wiegele, L.; Hamed, M.; Merkenschläger, A.M.; Fuell, G.; Junghanss, C.; Maletzki, C. Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1−/− Mice. *Cancers* 2019, 11, 1485. [CrossRef] [PubMed]

23. Machiels, J.P.H.; Todd Reilly, R.T.; Emens, L.A.; Ercolini, A.M.; Le, R.Y.; Weintraub, D.; Okyei, F.I.; Jaifee, E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.* 2001, 61, 3698–3697.

24. Sukkurwala, A.Q.; Adjemian, S.; Senovilla, L.; Michaud, M.; Spaggiari, S.; Vecchelli, E.; Baracco, E.E.; Galluzzi, L.; Zitvogel, L.; Kepp, O.; et al. Screening of novel immunogenic cell death inducers within the NCI mechanistic diversity set. *Oncoimmunology* 2014, 3, e28473. [CrossRef] [PubMed]

25. Hato, S.V.; Khong, A.; De Vries, I.J.M.; Lesterhuis, W.J. Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. *Clin. Cancer Res.* 2014, 20, 2831–2837. [CrossRef] [PubMed]

26. Gebremeskel, S.; Johnston, B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on clinical studies and considerations for combined therapies. *Oncotarget* 2015, 6, 41600–41619. [CrossRef] [PubMed]

27. Cui, G. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. *Front. Oncol.* 2021, 11. [CrossRef]

28. Wang, T.; Lee, L.H.; Vyas, M.; Zhang, L.; Ganesh, K.; Firat, C.; Segal, N.H.; Desai, A.; Hechtman, J.F.; Ntiamoah, P.; et al. Colorectal carcinoma with double somatic mismatch repair gene inactivation: Clinical and pathologica characteristics and response to immune checkpoint blockade. *Mod. Pathol.* 2019, 32, 1551–1562. [CrossRef]
29. Marabelle, A.; Le, D.T.; Ascietro, P.A.; Di Giacomo, A.M.; de Jesús-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 2020, 38, 1–10. [CrossRef]

30. André, T.; Shiu, K.-K.; Kim, T.W.; Jensen, B.V.; Jensen, L.H.; Punt, C.; Smith, D.; García-Carbonero, R.; Benavides, M.; Gibbs, P.; et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 2020, 383, 2207–2218. [CrossRef]

31. Rizvi, N.A.; Hellmann, M.D.; Brahmer, J.R.; Juergens, R.A.; Borghaei, H.; Gettinger, S.; Chow, L.Q.; Gerber, D.E.; Laurie, S.A.; Goldman, J.W.; et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2016, 34, 2969–2979. [PubMed]

32. Kanda, S.; Goto, K.; Shiraishi, H.; Kubo, E.; Tanaka, A.; Usumi, H.; Sunami, K.; Kitazono, S.; Mizugaki, H.; Horinouchi, H.; et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: A four arms phase IIb study. Ann. Oncol. 2016, 27, 2242–2250. [CrossRef] [PubMed]

33. Fujimoto, N.; Aoe, K.; Kozuki, T.; Oze, I.; Kato, K.; Kishimoto, T.; Hotta, K. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. Clin. Lung Cancer 2018, 19, e705–e707. [CrossRef]

34. Dudnik, E.; Moskovitz, M.; Rottenberg, Y.; Lobachov, A.; Mandelboim, R.; Shochat, T.; Urban, D.; Wollner, M.; Nechushtan, H.; Rotem, O.; et al. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥ 50%. Real-world data. Oncocimmunology 2021, 10. [CrossRef]

35. Principe, D.R.; Narbutis, M.; Kumar, S.; Park, A.; Viswakarma, N.; Dorman, M.J.; Kamath, S.D.; Grippo, P.J.; Fishel, M.L.; Hwang, R.F.; et al. Long-term germline nonsense treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunoimmunotherapy. Cancer Res. 2020, 80, 3101–3115. [CrossRef]

36. Baba, Y.; Nomoto, D.; Okadome, K.; Ishimoto, T.; Iwasuki, M.; Miyamoto, Y.; Yoshida, N.; Baba, H. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020, 111, 3132–3141. [CrossRef] [PubMed]

37. Seledtsov, VI.; Goncharov, A.G.; Seledtsova, G.V. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum. Vaccines Immunother. 2015, 11, 851–869. [CrossRef]

38. Martens, A.; Wistuba-Hamprecht, K.; Geukes Poppen, M.; Yuan, J.; Postow, M.A.; Wong, P.; Romano, E.; Khammari, A.; Dreno, B.; Capone, M.; et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin. Cancer Res. 2016, 22, 2908–2918. [CrossRef]

39. Weber, R.; Fleming, V.; Hu, X.; Nagibin, V.; Groth, C.; Altevogt, P.; Utikal, J.; Umansky, V. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front. Immunol. 2018, 9, 1310. [CrossRef]

40. Liu, Y.; Wei, G.; Cheng, W.A.; Dong, Z.; Sun, H.; Lee, Y.V.; Cha, S.-C.; Smith, D.L.; Kwak, L.W.; Qin, H. Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol. Immunother. 2018, 67, 1181–1195. [CrossRef]

41. Ahn, J.-H.; Lee, B.-H.; Kim, S.-E.; Kwon, B.-E.; Jeong, H.; Choi, J.R.; Kim, M.J.; Park, Y.; Kim, B.S.; Kim, D.H.; et al. A Novel Anti-PD-L1 Antibody Exhibits Antitumor Effects on Multiple Myeloma in Murine Models via Antibody-Dependent Cellular Cytotoxicity. Biomol. Ther. 2020, 29, 166–174. [CrossRef] [PubMed]

42. Hernandez, C.; Arasanz, H.; Chocarro, L.; Bocanegra, A.; Zuazo, M.; Fernandez-Hinojal, G.; Blanco, E.; Vera, R.; Escors, D.; Kochan, G. Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies. Int. J. Mol. Sci. 2020, 21, 2411. [CrossRef] [PubMed]

43. Wang, X.; Yang, X.; Zhang, C.; Wang, Y.; Cheng, T.; Duan, L.; Tong, Z.; Tan, S.; Zhang, H.; Saw, P.E.; et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc. Natl. Acad. Sci. USA 2020, 117, 6640–6650. [CrossRef] [PubMed]

44. Gu bin, M.M.; Esaulova, E.; Ward, J.P.; Malkova, O.N.; Runci, D.; Wong, P.; Noguchi, T.; Arthur, C.D.; Meng, W.; Alsphach, E.; et al. High-Dimensional Analysis of Cytokines Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 2018, 175, 1014–1030. [CrossRef]

45. Weiss, M.; Blazek, K.; Byrne, A.J.; Perocheau, D.P.; Udalova, I.A. IRF5 Is a Specific Marker of Inflammatory Macrophages In Vivo. Mediat. Inflamm. 2013, 2013, 1–9. [CrossRef]

46. Kwong, T.T.; Wong, C.H.; Zhou, J.Y.; Cheng, A.S.L.; Sung, J.J.Y.; Chan, A.W.H.; Chan, S.L. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Rep. 2021, 3, 100224. [CrossRef] [PubMed]

47. Suzuki, E.; Sun, J.; Kapoor, V.; Jassar, A.S.; Albelda, S.M. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol. Ther. 2007, 6, 880–885. [CrossRef]

48. Okamura, R.; Kato, S.; Lee, S.; Jimenez, R.E.; Sicklick, J.K.; Kurzrock, R. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J. Immunother. Cancer 2020, 8, e000438. [CrossRef]

49. Armstrong, S.; Al-Ghawi, H.; Helft, P.; House, M.G.; Spittler, A.J.; Wu, H.H.; Shahda, S. Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer. Clin. Colorectal Cancer 2018, 17, e229–e232. [CrossRef]

50. Lizardo, D.Y.; Kuang, C.; Hao, S.; Yu, J.; Huang, Y.; Zhang, L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim. Biophys. Acta Rev. Cancer 2020, 1874, 188447. [CrossRef]
51. Konstantinopoulos, P.A.; Luo, W.; Liu, J.F.; Gulhan, D.C.; Krasner, C.; Ishizuka, J.J.; Gockley, A.A.; Buss, M.; Growdon, W.B.; Crowe, H.; et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. *J. Clin. Oncol.* 2019, 37, 2786–2794. [CrossRef] [PubMed]

52. Maletzki, C.; Beyrich, F.; Hühns, M.; Klar, E.; Linnebacher, M. The mutational profile and infiltration pattern of murine MLH1−/− tumors: Concurrency, disparities and cell line establishment for functional analysis. *Oncotarget* 2016, 7, 53583–53598. [CrossRef] [PubMed]

53. Franken, N.A.P.; Rodermond, H.M.; Stap, J.; Haveman, J.; van Bree, C. Clonogenic assay of cells in vitro. *Nat. Protoc.* 2006, 1, 2315–2319. [CrossRef] [PubMed]

54. Maletzki, C.; Gladbach, Y.S.; Hamed, M.; Fuellen, G.; Semmler, M.-L.; Stenzel, J.; Linnebacher, M. Cellular vaccination of MLH1−/− mice—an immunotherapeutic proof of concept study. *Oncoimmunology* 2018, 7, e1408748. [CrossRef] [PubMed]

55. Rohde, S.; Lindner, T.; Polei, S.; Stenzel, J.; Borufka, L.; Achilles, S.; Hartmann, E.; Lange, F.; Maletzki, C.; Linnebacher, M.; et al. Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. *Oncotarget* 2017, 8, 69756–69767. [CrossRef]